Strategic funding Potential sales opportunity from Debiopharm Innovation Fund investment and ongoing venture interest. Engage to explore co-development or strategic partnerships for expanding access program automation and regulatory-compliant workflows.

Regulatory platform Position MedaSystems as a compliant, cloud-based platform for expanded access, post-trial access, and investigator-initiated studies. Target life sciences firms seeking centralized regulatory sequencing, real-world data capture, and sponsor-HCP collaboration.

Clinical engagement Leverage activity at neuro-oncology events (SNO meetings) to identify pharma and research sponsor needs in CNS indications. Offer specialized workflows and data capture tailored to oncology expanded access and investigator-initiated trials.

Growth signals Recent feature releases and customer growth indicate product-market fit and momentum. Approach expanding life sciences segments with scalability messaging and case studies demonstrating time-to-impact improvements.

Technology fit Existing tech stack and cloud foundations (AWS, Google Workspace, collaboration tools, and AI capabilities) align with mid-market pharma sponsors seeking secure, integrated RWD collection and automated approval workflows. Propose integrations and pilot deployments.